Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777–2789. https://doi.org/10.1080/21645515.2016.1199310

Article  PubMed  PubMed Central  Google Scholar 

Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B et al (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18(5):623–630. https://doi.org/10.1016/S1470-2045(17)30169-9

Article  CAS  PubMed  Google Scholar 

Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J et al (2017) Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18(2):212–220. https://doi.org/10.1016/S1470-2045(17)30007-4

Article  CAS  PubMed  Google Scholar 

Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and Ophthalmic Side effects. Retina 38(6):1063–1078. https://doi.org/10.1097/IAE.0000000000002181

Article  CAS  PubMed  Google Scholar 

Bloch-Michel E, Nussenblatt RB (1987) International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2):234–235. https://doi.org/10.1016/s0002-9394(14)74235-7

Article  CAS  PubMed  Google Scholar 

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918. https://doi.org/10.1016/S1470-2045(15)00083-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R et al (2016) Association of Pembrolizumab with Tumor Response and Survival among patients with Advanced Melanoma. JAMA 315(15):1600–1609. https://doi.org/10.1001/jama.2016.4059

Article  CAS  PubMed  Google Scholar 

Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN et al (2019) Sex differences in tolerability to Anti-programmed Cell death protein 1 therapy in patients with metastatic melanoma and Non-small Cell Lung Cancer: are we all Equal? Oncologist 24(11):e1148–e1155. https://doi.org/10.1634/theoncologist.2019-0094

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F et al (2021) Ophthalmic Immune-related adverse events after Anti-CTLA-4 or PD-1 Therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology 128(6):910–919. https://doi.org/10.1016/j.ophtha.2020.11.001

Article  PubMed  Google Scholar 

Kim YJ, Lee JS, Lee J, Lee SC, Kim TI, Byeon SH et al (2020) Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother 69(12):2441–2452. https://doi.org/10.1007/s00262-020-02635-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM (2018) Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 25(5):e403–e410. https://doi.org/10.3747/co.25.4047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R et al (2016) Pembrolizumab-triggered Uveitis: an additional surrogate marker for responders in Melanoma Immunotherapy? J Immunother 39(9):379–382. https://doi.org/10.1097/CJI.0000000000000143

Article  CAS  PubMed  Google Scholar 

Sun MM, Levinson RD, Filipowicz ADO, Anesi S, Kaplan HJ, Wang W et al (2020) Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 28(2):217–227. https://doi.org/10.1080/09273948.2019.1577978

Article  CAS  PubMed  Google Scholar 

Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26(9):1824–1829. https://doi.org/10.1093/annonc/mdv182

Article  CAS  PubMed  Google Scholar 

Men M, Tsui E (2022) Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab. Am J Ophthalmol Case Rep 27:101631. https://doi.org/10.1016/j.ajoc.2022.101631

Article  PubMed  PubMed Central  Google Scholar 

Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165. https://doi.org/10.1186/s40425-019-0645-6

Article  PubMed  PubMed Central  Google Scholar 

Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3(19):e59125. https://doi.org/10.1172/jci.insight.59125

Article  PubMed  PubMed Central  Google Scholar 

Mazharuddin AA, Whyte AT, Gombos DS, Patel N, Razmandi A, Chaudhry AL et al (2022) Highlights on ocular toxicity of Immune Checkpoint inhibitors at a US Tertiary Cancer Center. J Immunother Precis Oncol 5(4):98–104. https://doi.org/10.36401/JIPO-22-14

Article  PubMed  PubMed Central  Google Scholar 

Zhou L, Wei X (2021) Ocular Immune-related adverse events Associated with Immune checkpoint inhibitors in Lung Cancer. Front Immunol 12:701951. https://doi.org/10.3389/fimmu.2021.701951

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaudot F, Sève P, Rousseau A, Maria ATJ, Fournie P, Lozach P et al (2022) Ocular inflammation Induced by Immune Checkpoint inhibitors. J Clin Med 11(17):4993. https://doi.org/10.3390/jcm11174993

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dow ER, Yung M, Tsui E (2021) Immune Checkpoint inhibitor-associated Uveitis: review of treatments and outcomes. Ocul Immunol Inflamm 29(1):203–211. https://doi.org/10.1080/09273948.2020.1781902

Article  CAS  PubMed  Google Scholar 

Silpa-Archa S, Silpa-Archa N, Preble JM, Foster CS (2016) Vogt-Koyanagi-Harada syndrome: perspectives for immunogenetics, multimodal imaging, and therapeutic options. Autoimmun Rev 15(8):809–819. https://doi.org/10.1016/j.autrev.2016.04.001

Article  CAS  PubMed  Google Scholar 

Kuiper J, Rothova A, de Boer J, Radstake T (2015) The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. Prog Retin Eye Res 44:99–110. https://doi.org/10.1016/j.preteyeres.2014.11.003

Article  CAS  PubMed  Google Scholar 

Yoshida M, Kunikata H, Nakazawa T (2020) Intraocular concentrations of cytokines and chemokines in a unique case of Nivolumab-Induced Uveitis. Ocul Immunol Inflamm 28(6):850–853. https://doi.org/10.1080/09273948.2019.1582785

Article  CAS  PubMed  Google Scholar 

Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO et al (2011) CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22(3):121–130. https://doi.org/10.1016/j.cytogfr.2011.06.001

Article  CAS  PubMed  PubMed Central  Google Scholar